BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23773968)

  • 1. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
    Kozłowski M; Laudański W; Mroczko B; Szmitkowski M; Milewski R; Łapuć G
    Adv Med Sci; 2013; 58(2):227-34. PubMed ID: 23773968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
    Wang CS; Wu TL; Tsao KC; Sun CF
    Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of clinicopathological features and expression of biomarkers related to (18)F-FDG uptake in esophageal cancer.
    Schreurs LM; Smit JK; Pavlov K; Pultrum BB; Pruim J; Groen H; Hollema H; Plukker JT
    Ann Surg Oncol; 2014 Nov; 21(12):3751-7. PubMed ID: 24939624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
    Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
    Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
    Mitsuhashi A; Suzuka K; Yamazawa K; Matsui H; Seki K; Sekiya S
    Cancer; 2005 Feb; 103(4):724-30. PubMed ID: 15637689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
    Shang ZJ; Li JR; Li ZB
    Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum levels of VEGF and nitric oxide in esophageal squamous carcinoma patients and the clinical significance].
    Zhang T; Zhang F; Jiang T; Li XF; Wang YJ; Liu K
    Ai Zheng; 2002 Nov; 21(11):1248-50. PubMed ID: 12526227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
    Jiao XL; Chen D; Wang JG; Zhang KJ
    Eur Rev Med Pharmacol Sci; 2014; 18(4):509-15. PubMed ID: 24610617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer.
    Lu CL; Ji Y; Ge D; Guo J; Ding JY
    Dis Esophagus; 2011 May; 24(4):283-90. PubMed ID: 21087342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of hypoxia-inducible factor-1alpha and vessel endothelial growth factor in esophageal squamous cell carcinoma and clinico-pathological significance thereof].
    Yu ZT; Zhao HF; Shang XB
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2465-9. PubMed ID: 19080625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of tissue inhibitors of metalloproteinases (TIMP) on course and prognosis of head and neck squamous cell carcinoma].
    Klisho EV; Kondakova IV; Choĭnzonov EL; Shishkin DA; Cheremisina OV; Chuzhevskaia SIu
    Vopr Onkol; 2009; 55(6):717-21. PubMed ID: 20210014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.